A federal advisory panel unanimously backed an experimental drug being developed by Bayer to treat a dangerous lung disease, giving a boost to a potentially lucrative drug for the company.
via WSJ.com: US Business http://online.wsj.com/article/SB10001424127887324653004578652250483997038.html?mod=pls_whats_news_us_business_f
via WSJ.com: US Business http://online.wsj.com/article/SB10001424127887324653004578652250483997038.html?mod=pls_whats_news_us_business_f
Nessun commento:
Posta un commento